Glucocorticoid-Induced Ocular Hypertension and Glaucoma
dc.contributor.author | Harvey, Devon Hori | |
dc.contributor.author | Sugali, Chenna Kesavulu | |
dc.contributor.author | Mao, Weiming | |
dc.contributor.department | Ophthalmology, School of Medicine | |
dc.date.accessioned | 2024-06-11T15:04:49Z | |
dc.date.available | 2024-06-11T15:04:49Z | |
dc.date.issued | 2024-02-16 | |
dc.description.abstract | Glucocorticoid (GC) therapy is indicated in many diseases, including ocular diseases. An important side-effect of GC therapy is GC-induced ocular hypertension (GIOHT), which may cause irreversible blindness known as GC-induced glaucoma (GIG). Here, we reviewed the pathological changes that contribute to GIOHT including in the trabecular meshwork and Schlemm’s canal at cellular and molecular levels. We also discussed the clinical aspects of GIOHT/GIG including disease prevalence, risk factors, the type of GCs, the route of GC administration, and management strategies. | |
dc.eprint.version | Final published version | |
dc.identifier.citation | Harvey DH, Sugali CK, Mao W. Glucocorticoid-Induced Ocular Hypertension and Glaucoma. Clin Ophthalmol. 2024;18:481-505. Published 2024 Feb 16. doi:10.2147/OPTH.S442749 | |
dc.identifier.uri | https://hdl.handle.net/1805/41416 | |
dc.language.iso | en_US | |
dc.publisher | Dove Press | |
dc.relation.isversionof | 10.2147/OPTH.S442749 | |
dc.relation.journal | Clinical Ophthalmology | |
dc.rights | Attribution-NonCommercial 4.0 International | en |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0 | |
dc.source | PMC | |
dc.subject | Glucocorticoid | |
dc.subject | Intraocular pressure | |
dc.subject | Trabecular meshwork | |
dc.subject | Aqueous humor outflow | |
dc.subject | Mechanism | |
dc.subject | Treatment | |
dc.title | Glucocorticoid-Induced Ocular Hypertension and Glaucoma | |
dc.type | Article |